Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin

AbstractSmall-cell lung carcinoma (SCLC) is a type of lung cancer with neuroendocrine differentiation and a poor prognosis that is widely believed to arise in the central lung. Thyroid transcription factor-1 (TTF-1) is a peripheral marker of lung adenocarcinoma that is also highly expressed in SCLC. In this study, we examined whether SCLC is really a central-type tumor and the relationship between tumor location, TTF-1 expression and prognosis of SCLC.Ninety six SCLCs, diagnosed from biopsies or surgical materials, for which detailed computed tomography (CT) images were available, were collected consecutively from Japanese patients between 2004 and 2011. We examined the location of the primary tumor (central or peripheral) using thin-sliced CT, a TTF-1 immunohistochemical expression, and clinicopathology including prognosis.Of the 96 SCLCs, 74% (71/96) were of the peripheral type and found to have a significantly worse prognosis than central-type tumors. TTF-1 immunoreactivity was identified in 79 tumors (82%), 78% of which (62/79) were of the peripheral type and 22% of which were central. TTF-1 expression was significantly correlated with peripheral location (P = 0.030). Multivariate analysis revealed that high TNM stages and the peripheral location were independent markers for poor survival.The majority of SCLCs were of the peripheral type. The peripheral-type SCLC expressed TTF-1 more frequently and had a poorer prognosis than central-type tumors did. Further analysis on original sites of SCLC, using molecular methodology, or based on another ethnicity, should be warranted.

[1]  L. Lim,et al.  Thyroid transcription factor-1, hepatocyte nuclear factor-3beta, surfactant protein B, C, and Clara cell secretory protein in developing mouse lung. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  Stephen B. Baylin,et al.  Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer , 2003, Nature.

[3]  I Petersen,et al.  Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer , 2008, Oncogene.

[4]  Y. Yatabe,et al.  Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. , 2007, Cancer research.

[5]  Humam Kadara,et al.  Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis , 2011, Clinical Cancer Research.

[6]  N. Ordóñez.  Value of Thyroid Transcription Factor-1 Immunostaining in Distinguishing Small Cell Lung Carcinomas From Other Small Cell Carcinomas , 2000, The American journal of surgical pathology.

[7]  Mark A. Rubin,et al.  Clinical significance of TTF‐1 protein expression and TTF‐1 gene amplification in lung adenocarcinoma , 2009, Journal of cellular and molecular medicine.

[8]  C. Bingle.  Thyroid transcription factor-1. , 1997, The international journal of biochemistry & cell biology.

[9]  Leroy T. Canoles.  The Complexity of Thyroid Transcription Factor 1 with Both Pro- and Anti-Oncogenic Activities , 2013 .

[10]  R. Herbst,et al.  Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. , 2005, Clinical lung cancer.

[11]  J. Silverman,et al.  Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. , 2004, Human pathology.

[12]  Dietel,et al.  Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B , 2000, Histopathology.

[13]  Kenji Suzuki,et al.  Clinicopathologic features of peripheral squamous cell carcinoma of the lung. , 2004, The Annals of thoracic surgery.

[14]  Dietel,et al.  Expression of thyroid transcription factor‐1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites , 2000, Histopathology.

[15]  Andrew P. Stubbs,et al.  Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. , 2011, Cancer cell.

[16]  B. Chetaille,et al.  Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung , 2005, British Journal of Cancer.

[17]  J. Moldvay,et al.  The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas , 2008, Pathology & Oncology Research.

[18]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[19]  J. Whitsett,et al.  Expression of thyroid transcription factor-1(TTF-1) in fetal and neonatal human lung. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[21]  A. Nicholson,et al.  TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. , 2004, Human pathology.

[22]  F. Puglisi,et al.  Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. , 1997, Journal of clinical pathology.

[23]  P. Tam,et al.  A Germline Mutation ( A 339 V ) in Thyroid Transcription Factor-1 ( TITF-1 / NKX 2 . 1 ) in Patients With Multinodular Goiter and Papillary Thyroid Carcinoma , 2009 .

[24]  M. Fukuoka,et al.  Case‐Control Study for Lung Cancer and Cigarette Smoking in Osaka, Japan: Comparison with the Results from Western Europe , 1994, Japanese journal of cancer research : Gann.

[25]  S. Suster,et al.  Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. , 2001, Archives of pathology & laboratory medicine.

[26]  M. Peake,et al.  Trends in incidence of small cell lung cancer and all lung cancer. , 2012, Lung cancer.

[27]  D. Jackman,et al.  Small-cell lung cancer , 2005, The Lancet.

[28]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[29]  P. Tam,et al.  A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. , 2009, Journal of the National Cancer Institute.

[30]  M. Jordá,et al.  Analysis of thyroid transcription factor‐1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung , 2000, Journal of cutaneous pathology.

[31]  Tomoya Yamaguchi,et al.  NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. , 2013, Cancer cell.

[32]  Y. Tsutani,et al.  Prognostic impact of the primary tumor location based on the hilar structures in non-small cell lung cancer with mediastinal lymph node metastasis. , 2012, Lung cancer.

[33]  F. Puglisi,et al.  Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[34]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[35]  Y. Yatabe,et al.  TTF-1 Expression in Pulmonary Adenocarcinomas , 2002, The American journal of surgical pathology.

[36]  J. Lafitte,et al.  Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  C. Rudin,et al.  Small Cell Lung Cancer , 2022 .

[38]  Tobias Faust.  Pathology And Genetics Of Tumours Of The Lung Pleura Thymus And Heart , 2016 .

[39]  M. Mattéi,et al.  Thyroid nuclear factor 1 (TTF‐1) contains a homeodomain and displays a novel DNA binding specificity. , 1990, The EMBO journal.

[40]  S. Wiseman,et al.  Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. , 2003, Human pathology.